A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma
A study for patients with glioblastoma using study drub nivolumab
Sponsor: BMS
Enrolling: Male and Female Patients
IRB Number: AAAQ8187
U.S. Govt. ID: NCT02617589
Contact: Fabio Iwamoto: 212-342-0571 / fi2146@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558). Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow the bodys immune system to work against tumor cells. The effectiveness of BMS-936558 (nivolumab) in glioblastoma (GBM or brain cancer) will bedetermined by comparing the survival of subjects who receive the investigational drug BMS- 936558 (nivolumab) combined with radiotherapy to those who receive temozolomide with radiotherapy, an accepted therapy for newly diagnosed glioblastoma.
This study is closed
Fabio Iwamoto, MD
Do You Qualify?
Have you been diagnosed with glioblastoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Fabio Iwamoto